Watanabe T - Search Results

1

Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas.

Ohta T, Watanabe T, Katayama Y, Yoshino A, Yachi K, Ogino A, Komine C, Fukushima T. Ohta T, et al. Among authors: watanabe t. Oncol Rep. 2006 Nov;16(5):957-63. Oncol Rep. 2006. PMID: 17016577

2

Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.

Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T. Watanabe T, et al. J Neurooncol. 2003 Jan;61(2):171-6. doi: 10.1023/a:1022120325619. J Neurooncol. 2003. PMID: 12622456

3

Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.

Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Komine C, et al. Among authors: watanabe t. Brain Pathol. 2003 Apr;13(2):176-84. doi: 10.1111/j.1750-3639.2003.tb00017.x. Brain Pathol. 2003. PMID: 12744471 Free PMC article.

4

Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

Yoshino A, Katayama Y, Fukushima T, Watanabe T, Komine C, Yokoyama T, Kusama K, Moro I. Yoshino A, et al. Among authors: watanabe t. J Neurooncol. 2003 Jun;63(2):155-62. doi: 10.1023/a:1023935621976. J Neurooncol. 2003. PMID: 12825819

5

[Therapeutic efficacy and prognostic factors in diffuse astrocytomas].

Watanabe T, Komine C, Yokoyama T, Yoshino A, Katayama Y. Watanabe T, et al. No Shinkei Geka. 2003 Jul;31(7):767-73. No Shinkei Geka. 2003. PMID: 12884791 Japanese.

6

Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.

Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T. Watanabe T, et al. Clin Cancer Res. 2003 Oct 15;9(13):4884-90. Clin Cancer Res. 2003. PMID: 14581362

7

O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.

Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T. Watanabe T, et al. Int J Cancer. 2005 Feb 10;113(4):581-7. doi: 10.1002/ijc.20625. Int J Cancer. 2005. PMID: 15455376

8

Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea.

Fukushima T, Katayama Y, Watanabe T, Yoshino A, Ogino A, Ohta T, Komine C. Fukushima T, et al. Among authors: watanabe t. Clin Cancer Res. 2005 Feb 15;11(4):1539-44. doi: 10.1158/1078-0432.CCR-04-1625. Clin Cancer Res. 2005. PMID: 15746058

9

Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas.

Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T. Watanabe T, et al. J Neurooncol. 2005 Mar;72(1):57-62. doi: 10.1007/s11060-004-2160-x. J Neurooncol. 2005. PMID: 15803376 Clinical Trial.

10

The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.

Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T, Fukushima T. Ogino A, et al. Among authors: watanabe t. J Neuropathol Exp Neurol. 2005 May;64(5):398-403. doi: 10.1093/jnen/64.5.398. J Neuropathol Exp Neurol. 2005. PMID: 15892297

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,202 results

Search Page

Filters